The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 4 2 2021
medline: 16 7 2021
entrez: 3 2 2021
Statut: ppublish

Résumé

We sought to identify a subset of patients in whom an extended pelvic lymph node dissection during robot-assisted laparoscopic radical prostatectomy for localized prostate cancer could be omitted when preoperative prostate specific membrane antigen positron emission tomography showed no lymph node metastatic prostate cancer. A total of 434 patients who underwent prostate specific membrane antigen positron emission tomography prior to robot-assisted laparoscopic radical prostatectomy and extended pelvic lymph node dissection were retrospectively analyzed. Patients were excluded from analysis when the prostate specific membrane antigen positron emission tomography showed evidence of distant metastases. The primary outcome was whether a negative for metastases prostate specific membrane antigen positron emission tomography was able to correctly rule out pelvic lymp node metastases after extended pelvic lymph node dissection, ie its negative predictive value. Overall sensitivity, specificity, positive predictive value and negative predictive value of prostate specific membrane antigen positron emission tomography for the detection of pelvic lymp node metastases were 37.9%, 94.1%, 64.3% and 84.4%, respectively. The negative predictive value of prostate specific membrane antigen positron emission tomography in patients with intermediate risk prostate cancer was 91.6% (95% CI 86-97), compared to 81.4% (95% CI 77-86) in patients with high risk prostate cancer. When only assessing patients with <rT3 disease on multiparametric magnetic resonance imaging, 51/52 patients with intermediate risk prostate cancer had a true negative prostate specific membrane antigen positron emission tomography (negative predictive value=98.1%; 95% CI 94-100). In patients with high risk prostate cancer, extended pelvic lymph node dissection remains the gold standard staging method, as pelvic lymph node metastases are frequently missed in those with no lymph node metastatic prostate cancer on prostate specific membrane antigen positron emission tomography. Patients with intermediate risk prostate cancer and a radiological T-stage <rT3 on multiparametric magnetic resonance imaging are potential candidates to withhold an extended pelvic lymph node dissection in the presence of a "negative for lymph node metastases" prostate specific membrane antigen positron emission tomography.

Identifiants

pubmed: 33530746
doi: 10.1097/JU.0000000000001592
doi:

Substances chimiques

Antigens, Surface 0
FOLH1 protein, human EC 3.4.17.21
Glutamate Carboxypeptidase II EC 3.4.17.21

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1655-1662

Commentaires et corrections

Type : CommentIn

Auteurs

Dennie Meijer (D)

Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
Amsterdam University Medical Center, VU University, Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Hilda A de Barros (HA)

The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

Pim J van Leeuwen (PJ)

The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

Yves J L Bodar (YJL)

Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
Amsterdam University Medical Center, VU University, Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Henk G van der Poel (HG)

The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

Maarten L Donswijk (ML)

The Netherlands Cancer Institute, Department of Nuclear Medicine, Amsterdam, The Netherlands.

N Harry Hendrikse (NH)

Amsterdam University Medical Center, VU University, Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Amsterdam University Medical Center, VU University, Department of Clinical Pharmacology and Pharmacy, Amsterdam, The Netherlands.

R Jeroen A van Moorselaar (RJA)

Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

Jakko A Nieuwenhuijzen (JA)

Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

Daniela E Oprea-Lager (DE)

Amsterdam University Medical Center, VU University, Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.

André N Vis (AN)

Amsterdam University Medical Center, VU University, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.
The Netherlands Cancer Institute, Department of Urology, Prostate Cancer Network the Netherlands, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH